Status:

COMPLETED

A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

Lead Sponsor:

Ever Neuro Pharma GmbH

Collaborating Sponsors:

acromion GmbH

Geny Research Corp.

Conditions:

Vascular Dementia

Eligibility:

All Genders

50-85 years

Phase:

PHASE4

Brief Summary

This clinical trial was performed to assess the clinical efficacy and safety of two 4 week treatment courses of daily intravenous administration of Cerebrolysin (20mL \[milliliter\] IV \[intravenous\]...

Eligibility Criteria

Inclusion

  • Men or post-menopausal women between 50 and 85 years
  • Clinical diagnosis of vascular dementia according to NINDS-AIREN criteria
  • CT or MRI results compatible with clinical diagnosis
  • MMSE score between 10 and 24, both inclusive
  • Modified Hachinski Ischemic Score \>4
  • Hamilton Depression Scale score of less than or equal to 15
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Informed consent given by the patient and/or the next-of-kin

Exclusion

  • Gastric ulcer associated with intolerance of acetylsalicylic acid treatment
  • Severe psychotic features, schizophrenia, depression, agitation or behavioral problems within the last three months that could lead to difficulty complying with the protocol
  • Any severe systemic illness or unstable medical condition that could lead to difficulty complying with the protocol or significantly limits life span.
  • Patients who in the investigator's opinion, would not comply with study procedures
  • Any significant neurological disease other than vascular dementia, such as Parkinson's disease, epilepsy, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis
  • History of alcohol or substance abuse or dependence within the past two years
  • Patients with a history of systemic cancer within the past two years
  • Severe congestive heart failure or malignant, uncontrollable hypertension
  • Participation in a clinical trial with an investigational drug in the past four weeks

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2007

Estimated Enrollment :

242 Patients enrolled

Trial Details

Trial ID

NCT00947531

Start Date

October 1 2006

End Date

August 1 2007

Last Update

February 21 2024

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

Chita State Medical Academy/Regional Psychiatric Hospital No. 2

Chita, Russia

2

Chita State Medical Academy/Veterans Hospital

Chita, Russia

3

Irkutsk State Institute of Postgraduate Education/Regional Clinical Hospital

Irkutsk, Russia

4

Kazan State Medical University/Municipal Clinical Hospital No. 6

Kazan', Russia